Aptose Biosciences Inc (APTO)

[dcaf7]

Pre-ASH run? Tuspetinib will be presented at Post-ASH 2023 AML Highlights with discussions on selected AML abstracts from the 65th ASH Annual Meeting.
https://www.vjhemonc.com/feature/post-ash-2023-aml-highlights/
Actually, I am intrigued by other talk in Session 2: FLT3-Mutated Disease, entitled "The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 AML: Analysis of Pethema Quiwi". It looks like, the authors found a group of genes that predicts responsiveness of AML patients with FLT3 WT to FLT3 inhibitors. Quiz, like Tusp, works in FLT3 WT population. Interesting. Could be useful for Tusp as well.